Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Chemotherapy caused nail grooves and separation, but they healed after treatment stopped.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

CS12192 effectively treats alopecia areata with better safety than current options.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.

Ruxolitinib can help regrow hair in severe alopecia areata.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

An 11-year-old girl's hair loss was caused by a Cladosporium fungal infection, which was cured with itraconazole treatment.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

The treatment was not recommended due to limited effectiveness and significant side effects.

Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.

A woman with Budd-Chiari syndrome improved after treatment and needs a liver transplant, highlighting the importance of considering non-criteria antiphospholipid syndrome in similar cases.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.